Information Provided By: 
Fly News Breaks for July 21, 2017
IRWD
Jul 21, 2017 | 06:02 EDT
JPMorgan analyst Anupam Rama downgraded Ironwood Pharmaceuticals to Neutral with a slightly reduced price target of $19. While Linzess remains in a strong position, it could take before "meaningful value creation" from the company's pipeline is realized, given that late-stage trial results are likely multi-years out, Rama tells investors in a research note. The analyst would look to become more constructive on a pullback.
News For IRWD From the Last 2 Days
There are no results for your query IRWD
